Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis

Author(s): Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li* and Su Shen*

Volume 27, Issue 19, 2021

Published on: 16 September, 2020

Page: [2317 - 2324] Pages: 8

DOI: 10.2174/1381612826666200916144249

Price: $65

Abstract

Background: Conflicting data exist regarding the influence of thiopurines exposure on adverse pregnancy outcomes in female patients with inflammatory bowel disease (IBD).

Objective: The aim of this study was to provide an up-to-date and comprehensive assessment of the safety of thiopurines in pregnant IBD women.

Methods: All relevant articles reporting pregnancy outcomes in women with IBD received thiopurines during pregnancy were identified from the databases (PubMed, Embase, Cochrane Library, and ClinicalTrials.gov) with the publication data up to April 2020. Data of included studies were extracted to calculate the relative risk (RR) of multiple pregnancy outcomes: congenital malformations, low birth weight (LBW), preterm birth, small for gestational age (SGA), and spontaneous abortion. The meta-analysis was performed using the random-effects model.

Results: Eight studies matched with the inclusion criteria and a total of 1201 pregnant IBD women who used thiopurines and 4189 controls comprised of women with IBD received drugs other than thiopurines during pregnancy were included. Statistical analysis results demonstrated that the risk of preterm birth was significantly increased in the thiopurine-exposed group when compared to IBD controls (RR, 1.34; 95% CI, 1.00-1.79; p=0.049; I2 =41%), while no statistically significant difference was observed in the incidence of other adverse pregnancy outcomes.

Conclusion: Thiopurines used in women with IBD during pregnancy is not associated with congenital malformations, LBW, SGA, or spontaneous abortion, but appears to have an association with an increased risk of preterm birth.

Keywords: Thiopurines, azathioprine, 6-mercaptopurine, pregnancy, inflammatory bowel disease, Meta-Analysis.

« Previous Next »
[1]
Friedman S. Pregnancy and IBD: Timing Is Everything. Dig Dis Sci 2017; 62(8): 1847-9.
[http://dx.doi.org/10.1007/s10620-017-4498-x] [PMID: 28243812]
[2]
Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western Countries Gastroenterology 2018; 155(4): 1079-89.
[http://dx.doi.org/10.1053/j.gastro.2018.06.043]
[3]
Bell SJ, Flanagan EK. Updates in the management of inflammatory bowel disease during pregnancy. Med J Aust 2019; 210(6): 276-80.
[http://dx.doi.org/10.5694/mja2.50062] [PMID: 30905081]
[4]
Pinder M, Lummis K, Selinger CP. Managing inflammatory bowel disease in pregnancy: current perspectives. Clin Exp Gastroenterol 2016; 9: 325-35.
[http://dx.doi.org/10.2147/CEG.S96676] [PMID: 27789969]
[5]
Wall GC, Muktar H, Effken C, Mahajan PB. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease. Pharmacotherapy 2018; 38(2): 259-70.
[http://dx.doi.org/10.1002/phar.2067] [PMID: 29197117]
[6]
Saarikoski S, Seppälä M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol 1973; 115(8): 1100-6.
[http://dx.doi.org/10.1016/0002-9378(73)90559-0] [PMID: 4348000]
[7]
GlaxoSmithKline. Imuran (azathioprine) package insert. Brentford, England 2007.
[8]
Hendy P, Chadwick G, Hart A. IBD: reproductive health, pregnancy and lactation. Frontline Gastroenterol 2015; 6(1): 38-43.
[http://dx.doi.org/10.1136/flgastro-2014-100430] [PMID: 28839793]
[9]
Gaidos JK, Kane SV. Managing IBD Therapies in Pregnancy. Curr Treat Options Gastroenterol 2017; 15(1): 71-83.
[http://dx.doi.org/10.1007/s11938-017-0123-5] [PMID: 28181180]
[10]
Shim L, Eslick GD, Simring AA, Murray H, Weltman MD. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohn’s Colitis 2011; 5(3): 234-8.
[http://dx.doi.org/10.1016/j.crohns.2011.01.009] [PMID: 21575887]
[11]
Coelho J, Beaugerie L, Colombel JF, et al. CESAME Pregnancy Study Group (France). Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60(2): 198-203.
[http://dx.doi.org/10.1136/gut.2010.222893] [PMID: 21115547]
[12]
Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108(3): 433-40.
[http://dx.doi.org/10.1038/ajg.2012.430] [PMID: 23318480]
[13]
Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124(1): 9-17.
[http://dx.doi.org/10.1053/gast.2003.50014] [PMID: 12512024]
[14]
Cleary BJ, Källén B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85(7): 647-54.
[http://dx.doi.org/10.1002/bdra.20583] [PMID: 19343728]
[15]
Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn’s disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102(7): 1406-13.
[http://dx.doi.org/10.1111/j.1572-0241.2007.01216.x] [PMID: 17437503]
[16]
Komoto S, Motoya S, Nishiwaki Y, et al. Japanese study group for pregnant women with IBD. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res 2016; 14(2): 139-45.
[http://dx.doi.org/10.5217/ir.2016.14.2.139] [PMID: 27175114]
[17]
Bröms G, Granath F, Linder M, Stephansson O, Elmberg M, Kieler H. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis 2014; 20(6): 1091-8.
[http://dx.doi.org/10.1097/MIB.0000000000000060] [PMID: 24810137]
[18]
Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(1): 15-22.
[http://dx.doi.org/10.1002/ibd.22948] [PMID: 22434610]
[19]
Hutson JR, Matlow JN, Moretti ME, Koren G. The fetal safety of thiopurines for the treatment of inflammatory bowel disease in pregnancy. J Obstet Gynaecol 2013; 33(1): 1-8.
[http://dx.doi.org/10.3109/01443615.2012.716106] [PMID: 23259868]
[20]
Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol 2015; 34(5): 445-59.
[http://dx.doi.org/10.1177/0960327114550882] [PMID: 25378092]
[21]
Gonzalez-Suarez B, Sengupta S, Moss AC. Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis. World J Gastroenterol 2017; 23(45): 8082-9.
[http://dx.doi.org/10.3748/wjg.v23.i45.8082] [PMID: 29259384]
[22]
Kanis SL, de Lima-Karagiannis A, de Boer NKH, van der Woude CJ. Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study. Clin Gastroenterol Hepatol 2017; 15(8): 1232-41.
[http://dx.doi.org/10.1016/j.cgh.2017.02.041]
[23]
Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015; 8(1): 2-10.
[http://dx.doi.org/10.1111/jebm.12141] [PMID: 25594108]
[24]
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283(15): 2008-12.
[http://dx.doi.org/10.1001/jama.283.15.2008] [PMID: 10789670]
[25]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[26]
Nørgård B, Pedersen L, Fonager K, Rasmussen SN, Sørensen HT. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003; 17(6): 827-34.
[http://dx.doi.org/10.1046/j.1365-2036.2003.01537.x] [PMID: 12641505]
[27]
Nørgård BM. Birth outcome in women with ulcerative colitis and Crohn’s disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Dan Med Bull 2011; 58(12): B4360.
[PMID: 22142578]
[28]
Szymańska E, Kisielewski R, Kierkuś J. Reproduction and Pregnancy in Inflammatory Bowel Disease - Management and Treatment Based on Current Guidelines. J Gynecol Obstet Hum Reprod 2020; 50(3): 101777.
[http://dx.doi.org/10.1016/j.jogoh.2020.101777] [PMID: 32315763]
[29]
Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56(6): 830-7.
[http://dx.doi.org/10.1136/gut.2006.108324] [PMID: 17185356]
[30]
de Lima-Karagiannis A, Zelinkova-Detkova Z, van der Woude CJ. The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies. Am J Gastroenterol 2016; 111(9): 1305-12.
[http://dx.doi.org/10.1038/ajg.2016.254] [PMID: 27349339]
[31]
Kane S. IBD: Activity of IBD during pregnancy. Nat Rev Gastroenterol Hepatol 2013; 10(10): 571-2.
[http://dx.doi.org/10.1038/nrgastro.2013.152] [PMID: 23938453]
[32]
Bröms G, Granath F, Stephansson O, Kieler H. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment. Scand J Gastroenterol 2016; 51(12): 1462-9.
[http://dx.doi.org/10.1080/00365521.2016.1208269] [PMID: 27739352]
[33]
Kammerlander H, Nielsen J, Kjeldsen J, Knudsen T, Friedman S, Nørgård B. The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23(6): 1011-8.
[http://dx.doi.org/10.1097/MIB.0000000000001102] [PMID: 28346274]
[34]
Rottenstreich A, Fridman Lev S, Rotem R, et al. Disease flare at prior pregnancy and disease activity at conception are important determinants of disease relapse at subsequent pregnancy in women with inflammatory bowel diseases. Arch Gynecol Obstet 2020; 301(6): 1449-54.
[http://dx.doi.org/10.1007/s00404-020-05557-8] [PMID: 32377786]
[35]
Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002; 65(5): 240-61.
[http://dx.doi.org/10.1002/tera.10043] [PMID: 11967923]
[36]
Koren G. Ethical framework for observational studies of medicinal drug exposure in pregnancy. Teratology 2002; 65(4): 191-5.
[http://dx.doi.org/10.1002/tera.10038] [PMID: 11948565]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy